Abstract S125. 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3+7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
Dr Micheal Lübbert, Universitätsklinikum Freiburg, Freiburg, Germany.
Recorded @ Vienna Messe Center, June 11, 2022